ArticleOpen heart2021
Characteristics of infective endocarditis in a cancer population.
Article in Open heart, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 21 citations in OpenAlex.
- Infective Endocarditis on Aortic Valve: From Diagnosis to Cardiac Surgical Intervention-Narrative Review.Journal of clinical medicine · 2026Review
- Changing Patterns in Infective Endocarditis: A Contemporary Epidemiological Perspective.Pathogens (Basel, Switzerland) · 2026Review
- Aortic Root Abscess With Left Atrial Fistula: A Rare and Life-Threatening Complication of Infective Endocarditis.JACC. Case reports · 2026Article
- Review
- Infective Endocarditis Following Coil Embolization for a Visceral Pseudoaneurysm: A Case Report.Cureus · 2025Article
- The Benefit and Harm of an Implantable Cardiac Defibrillator in a Patient with Heart Failure: A Case Report and Literature Review.Reports (MDPI) · 2025Article
- Unexpected Infective Endocarditis: Towards a New Alert for Clinicians.Journal of clinical medicine · 2024Review
- Emerging and Re-Emerging Pathogens in Valvular Infective Endocarditis: A Review.Pathogens (Basel, Switzerland) · 2024Review
- Novel Diagnostic Methods for Infective Endocarditis.International journal of molecular sciences · 2024Review
- Systemic embolization due to non-bacterial thrombotic endocarditis: An autopsy case report and mini review of the literature.SAGE open medical case reports · 2024Article
- Mitral Valve Endocarditis - An Unusual Culprit in a Cancer Patient.Arquivos brasileiros de cardiologia · 2023Article
- Article
- Editorial: Cardio-oncology: mechanisms and therapeutics.Frontiers in cardiovascular medicine · 2023Article
- Review
Corrections and comments
- Erratum issuedCorrection:2021
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
backgroundInfective endocarditis (IE) is more common in patients with cancer as compared with the general population. Due to an immunocompromised state, the need for invasive procedures, hypercoagulability and the presence of indwelling catheters, patients with cancer are particularly predisposed to the development of IE.
objectivesLimited information exists about IE in patients with cancer. We aimed to evaluate the characteristics of patients with cancer and IE at our tertiary care centre, including a comparison of the microorganisms implicated and their association with mortality.
methodsA retrospective chart review of patients with cancer who had echocardiography for suspicion of endocarditis was conducted. A total of 56 patients with a confirmed diagnosis of cancer and endocarditis, based on the modified Duke criteria, were included in the study. Baseline demographics, risk factors for developing IE, echocardiography findings, microbiology and mortality data were analysed.
resultsFollowing the findings of vegetations by echocardiography, the median survival time was 8.5 months.
conclusionsOverall survival of patients with cancer and endocarditis is poor, with a worse outcome in patients with SAE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.